None listed
Conditions
Brief summary
This feasibility trial will look at how follow up models could be changed to fit better alongside patient’s lives whilst still providing safe care.
Interventions
A custom made web based model of follow up for non curative lung cancer patients who have completed first line therapy and entering surveillance. On completion of systemic therapy or palliative radiotherapy recruited patients will be randomised 1:1 between the standard of care (SOC) arm and the web based model. Both groups will follow the standard three monthly follow-up schedule. Both groups will be required to complete quality of life (QOL), anxiety, supportive care needs, and healthcare utilisation at all assessment points, on-line via the web based tool (Max 20 mins to complete). Patients in the trial arm will complete the web based tool at home assessing for signs of progression, at each three month assessment point or triggered by the patient. If not completed at 3 month assessment point, the patient will be prompted with an email and/or text reminder. Triage symptoms include pain, breathlessness, cough, haemoptysis, fatigue, performance status, and weight loss. Completion of this tool will trigger a response to clinical staff, via email, notifying if the patient needs to be contacted for further assessment on site. This assessment point will be in line with the patients re-staging imaging with CT. SOC arm patients will continue with onsite three monthly clinic assessments and imaging with CT. Both groups will be able to access the Cancer and Blood department between assessment points should they develop symptoms of concern. Both groups will be in surveillance until 12 months from their recruitment date. The web based tool will be manually checked alongside the clinic schedule for the trial patients, to ensure accuracy, adherence, and safety of the alert system.
Sponsors
Study design
Eligibility
Inclusion criteria
Inclusion criteria Patients over 18 years of age with confirmed non-small cell lung cancer stage 3b (non-curative intent) and stage 4, small cell lung cancer patients, and patients with mesothelioma. Participants must have competency to sign consent. Patients must have completed standard of care systemic treatment for their cancer. Patients must have an ECOG performance status of 0 -3
Exclusion criteria
Patients with an EGFR or ALK mutation on Tyrosine Kinase Inhibitor therapy. Patients on systemic treatments including maintenance chemotherapy or immunotherapy. Patients who are progressing to palliative radiotherapy treatment. All non-English speaking patients who would require an interpreter.